Attention Guest: Please make sure that you are using a unique password to login to MESO. If you have used your MESO password on another website, change it immediately. You should NEVER share the same login credentials on multiple websites.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Discussion in 'Men's Economics' started by Michael Scally MD, Dec 21, 2012.

  1. Michael Scally MD

    Michael Scally MD Doctor of Medicine

    BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
    Biomarin
    BioMarin Pharmaceutical Inc.: NASDAQ:BMRN quotes & news - Google Finance

    The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates.

    Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN®(sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS).

    Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers and BMN-111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia.


    Drug trial gives hope to Pompe sufferer
    Pompe Sufferer Gets Hope From Drug Trial | Stuff.co.nz


    Maga JA, Zhou J, Kambampati R, et al. Glycosylation-independent lysosomal targeting of acid ?-glucosidase enhances muscle glycogen clearance in Pompe mice. Journal of Biological Chemistry. Glycosylation-independent lysosomal targeting of acid ?-glucosidase enhances muscle glycogen clearance in Pompe mice

    We have used a peptide-based targeting system to improve lysosomal delivery of acid ?-glucosidase (GAA), the enzyme deficient in patients with Pompe disease. Human GAA was fused to the Glycosylation-Independent Lysosomal Targeting (GILT) tag, which contains a portion of insulin-like growth factor II (IGF-II), to create an active, chimeric enzyme with high affinity for the cation-independent mannose 6-phosphate receptor (CI-MPR). GILT-tagged GAA was taken up by L6 myoblasts about 25-fold more efficiently than was recombinant human GAA (rhGAA). Once delivered to the lysosome, the mature form of GILT-tagged GAA was indistinguishable from rhGAA and persisted with a half-life indistinguishable from rhGAA. GILT-tagged GAA was significantly more effective than rhGAA in clearing glycogen from numerous skeletal muscle tissues in the Pompe mouse model. The GILT-tagged GAA enzyme may provide an improved enzyme replacement therapy for Pompe disease patients.


    Capsule

    Background: Acid-?-glucosidase, an enzyme replacement therapy for Pompe disease, is poorly targeted to lysosomes when relying on phosphomannose residues.

    Results: Fusing IGF-II to acid-?-glucosidase resulted in more efficient uptake and glycogen clearance from muscle of Pompe mice.

    Conclusion: Enhanced binding to the CI-MPR enabled improved glycogen clearance in Pompe mice.

    Significance: BMN 701 is now being tested for Pompe disease in human clinical studies.
     
    Last edited: Dec 21, 2012
  2. Michael Scally MD

    Michael Scally MD Doctor of Medicine

    Crunkhorn S. Trial watch: Enzyme replacement success in Phase III trial for rare metabolic disorder. Nat Rev Drug Discov 2013;12(1):12. http://www.nature.com/nrd/journal/v12/n1/full/nrd3929.html

     
  3. Michael Scally MD

    Michael Scally MD Doctor of Medicine

    [BUY] BioMarin Acquires Zacharon Pharmaceuticals
    BioMarin Acquires Zacharon Pharmaceuticals (NASDAQ:BMRN)

    Lead Program Focused on the Oral Treatment of MPS III

    Acquisition Augments Existing Analytical Capabilities and Expertise in Glycobiology